EP2699268A2 - Nouveaux conjugués liant-principe actif (adc) et leur utilisation - Google Patents

Nouveaux conjugués liant-principe actif (adc) et leur utilisation

Info

Publication number
EP2699268A2
EP2699268A2 EP12718624.5A EP12718624A EP2699268A2 EP 2699268 A2 EP2699268 A2 EP 2699268A2 EP 12718624 A EP12718624 A EP 12718624A EP 2699268 A2 EP2699268 A2 EP 2699268A2
Authority
EP
European Patent Office
Prior art keywords
group
hydrogen
formula
denotes
point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12718624.5A
Other languages
German (de)
English (en)
Inventor
Hans-Georg Lerchen
Lars Linden
Sherif El Sheikh
Jörg WILLUDA
Charlotte Christine KOPITZ
Joachim Schuhmacher
Simone Greven
Christoph Mahlert
Beatrix Stelte-Ludwig
Sven Golfier
Rudolf Beier
Iring Heisler
Axel Harrenga
Karl-Heinz Thierauch
Sandra Bruder
Heike Petrul
Hannah JÖRIßEN
Sandra Borkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Priority to EP19150066.9A priority Critical patent/EP3501546A3/fr
Priority to EP12718624.5A priority patent/EP2699268A2/fr
Publication of EP2699268A2 publication Critical patent/EP2699268A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present application relates to novel, directed against the target C4.4a binder-drug conjugates (ADCs) of ⁇ , ⁇ -dialkylauristatins, active metabolites of these ADCs, methods for producing these ADCs, the use of these ADCs for the treatment and / or prevention of Diseases and the use of these ADCs for the preparation of medicaments for the treatment and / or prevention of diseases, especially hyperproliferative and 7 or angiogenic diseases such as cancer.
  • Such treatments may be monotherapy or in combination with other medicines or other therapeutic measures.
  • Cancers are the result of uncontrolled cell growth in a variety of tissues, in many cases the new cells invade existing tissues (invasive growth) or they metastasize to distant organs. Cancers occur in various organs and often have tissue-specific disease courses. Therefore, the term cancer as a generic term describes a large group of defined diseases of various organs, tissues and cell types.
  • chemotherapeutic agents administered parenterally today are often not targeted to tumor tissue or tumor cells, but are nonspecifically distributed in the body by systemic administration, i. even in places where drug exposure is undesirable, such as in healthy cells, tissues, and organs. This can lead to unwanted side effects and even serious general toxic effects, which then often severely limit the therapeutically usable dose range of the active substance or require a complete cessation of the medication.
  • trastuzumab Herceptin
  • rituximah Renillab
  • cetuximab Erbitux
  • bevacizumab Avastin
  • small molecule drug binders can also be used as binders that selectively bind to a particular target, such as a receptor [see, e.g. E. Ruoslahti et al., Science 279, 377-380 (1998); D. Karkan et al., PLoS ONE 3 (6), e2469 (June 25, 2008)]. Also known are conjugates of cylotoxic agent and addressing ligand, which have a defined cleavage site between ligand and drug to release the drug.
  • target breakpoint may be, for example, in a peptide chain which can be selectively cleaved at a particular site by a specific enzyme at the site of action [see, e.g. R. A, Firestone and L.A. Telan, US Patent Application US 2002/0147138].
  • C4.4a (gene: LYPD3) was first described as a metastasis-associated cell surface protein in rat pancreatic tumor cells (R Harborl M. et al., Oncogene 1998, 17 (15): 1989-2002). Human C4.4a was isolated from its placental cDNA library (Würfel, J. et al., Gene 2001, 262: 35-41). C4.4a shows structural homology to the uPA receptor and contains two LY6 domains that share the typical three-finger folding motif and are linked by 9 disulfide bonds (Jacobsen B.
  • C4.4a is anchored in the cell via glycophosphatidylinositol (GPI).
  • GPI glycophosphatidylinositol
  • the protein is highly glycosylated and contains numerous - and O- glycosylation sites.
  • C4.4a shows strong expression in tumor cells of lung cancer, colon cancer, breast cancer, uterine cancer pancreatic cancer, kidney cancer, head and neck tumors and melanoma.
  • RNA analyzes showed C4.4a expression in - 50% of primary lung tumors and -75% of lung cancer metastases, whereas expression in healthy lung tissue was undetectable (Würfel J. et al., Gene 2001, 262: 35- 41).
  • C4.4a can be used as a prognostic marker, with high C4.4a expression correlating with poor prognosis (Hansen L. et al ,, Lung Cancer 2007, 58: 260-266).
  • colon cancer C4.4a is cleaved off the tumor cell surface and can be used as a prognostic serum marker (Konishi, K., et al., Cancer Science 2010).
  • a detailed expression analysis of melanoma revealed that C4.4a is present in ⁇ 60% of the primary malignancies Melanoma and is expressed in 100% of lymph node and skin metastases (sammlungr S. et al., Juvest Dermatol., 2001, 116 (2): 344-347).
  • C4.4a is an ideal target for tumor therapy because C4.4a expression in healthy tissues is restricted to skin keratinocytes and esophageal endothelial cells as well as placental cells (Würfel J. et al., Gene 2001, 262: 35-41).
  • WO01 / 23553 describes the use of a C4.4a inhibitor (eg an anti-C4.4a antibody) which can inhibit C4.4a expression or activity in cancer therapy. The exact function of C4.4a is unknown.
  • C4.4a is thought to play a role in tumor cell invasion, presumably through interaction with the extracellular matrix (Renderl M, et al., Oncogene 1998, 17 (15): 1989-2002; Paret C. et al. British Journal of Cancer 2007, 97: 1146-1156).
  • Potential ligands are laminin I and 5, as well as galectin 3 (Paret C, Int J. Cancer 2005, 115: 724-733).
  • Auristatin E (AE) and monomethylauristatin E (MMAE) are synthetic analogues of the statins, a special group of linear pseudopeptides originally isolated from marine sources, some of which have very potent cytotoxic activity against tumor cells [for a review, see, eg GR Pettit, Prague. Chem. Org. Prod. 70, 1-79 (1997); GR Pettit et al, Anti-Cancer Dr g Design 10, 529-544 (1995); GR Pettit et al, AntiCancer Drug Design 13, 243-277 (1998) 1.
  • MMAE Monomethylauristatin E
  • MMAE has the disadvantage of a comparatively high systemic toxicity.
  • MMAE is used in particular in conjunction with enzymatically cleavable valine citrulline linkers in the ADC setting for more targeted tumor therapy [WO 2005/081711-A2; S.O. Doronina et al., Bioconjugate Chem. 17, 114-124 (2006)].
  • MMAE is preferably released intracellularly from corresponding ADCs.
  • MMAE is in an application in the form of (ADCs) not compatible with linker (linker) between antibody and drug, which have no enzymatically cleavable target breakpoint [SO Doronina et al., Bioconjugate Chem. 17, 114-124 (2006)].
  • Monomethylauristatin F is an auristatin derivative having a C-terminal phenylalanine moiety which has only moderate anti-proliferative activity compared to MMAE. This is most likely due to the free carboxyl group which, due to its polarity and charge, adversely affects the cellularity of this compound.
  • MMAF-OMe methyl ester of MMAF
  • MMAF-OMe methyl ester of MMAF
  • MMAF-OMe has been described as a neutrally charged, prodrug prodrug, which has several orders of magnitude increased in vitro cytotoxicity to various carcinoma cell lines compared to MMAF [SO Doronina et al., Bioconjugate Chem. 17, 114-124 (2006)]. It is believed that this effect is caused by MMAF itself, which is rapidly released by intracellular ester hydrolysis after uptake of the prodrug into the cells.
  • active compound compounds based on simple ester derivatives are generally subject to the risk of chemical instability as a result of unspecific ester hydrolysis independent of the intended site of action, for example by esterases present in the blood plasma; this can significantly limit the applicability of such compounds in therapy.
  • MMAF Monomethylauristatin F
  • auristatin analogues with a C-terminal, amidically substituted phenylalanine unit are described in WO 01/18032-A2.
  • WO 02/088172-A2 and WO 2007/008603-A1 claim MMAF analogs which relate to side-chain modifications of phenylalanine, and in WO 2007/008848-A2 those in which the carboxyl group of phenylalanine is modified , Auristatin conjugates linked via the C-terminus have recently been described in WO 2009/1 17531 -AI [see also S.O. Doronina et al., Bioconjugate Chem. 19, 1960-1963 (2008) 1.
  • auristatin derivatives such as MMAE and MMAF are also substrates for transporter proteins which are expressed by many tumor cells, which can lead to a development of resistance to these active substances.
  • ADCs novel binder-drug conjugates
  • the present invention relates to binder-active compound conjugates of the general formula (Ia)
  • n is a number from 1 to 50
  • AK is a binder
  • group ⁇ -G-L'-BL 2 - ⁇ is a linker
  • ⁇ denotes the linking parts with the group AK and ⁇ denotes the point of attachment with the nitrogen atom, D for a group of the formula
  • n ' denotes the point of attachment to the nitrogen atom
  • R 1 is hydrogen or methyl
  • R 2 is isopropyl, isobutyl, sec-butyl, fer. '- butyl, phenyl, benzyl, 1 -
  • # 5 denotes the site of attachment to the carbonyi group, with the NO group contained therein being a mono- or bicyclic, optionally substituted heterocycle of the formula
  • R ' is hydrogen, methyl, ethyl, propyl, tert. Butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i 0 is benzoyl
  • R 11 is benzyl which may be substituted in the phenyl group by methoxycarbonyl or carboxyl,
  • R 5 is hydrogen, methyl or a group of the formula
  • R 12 is phenyi which is reacted with methoxycarbonyl, carboxyi or a group of the formula S (C) ⁇ ⁇ ()! ⁇ can be substituted,
  • R ' 3 is phenyi which may be substituted with methoxycarbonyl or carboxyi
  • R zo is hydrogen or hydroxy
  • T 2 represents phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl
  • R J5 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Compounds of the invention are the compounds of the formula (ia) and (I) and their salts, solvates and solvates of the salts, the compounds of the formulas (Ia) and (I) of the following formulas and their salts, solvates and solvates of the salts and the compounds of formula (Ia) and (I), referred to below as exemplary embodiments, and their salts, solvates and solvates of the salts, as far as the compounds of formula (Ia) and (I) below are not already salts , Solvates and solvates of the salts.
  • the compounds according to the invention may exist in different stereoisomeric forms, ie in the form of configurational isomers or optionally also as conformational isomers (enantiomers and / or diastereomers, including those of atropisomers).
  • the present invention therefore includes the enantiomers and diastereoisomers and their respective mixtures. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform constituents can be in a known manner isolate; Preferably, chromatographic methods are used for this, in particular HPLC chromatography on achiral or chiral phase.
  • the present invention encompasses all tautomeric forms.
  • the present invention also includes all suitable isofopic variants of the compounds of the invention.
  • An isotopic variant of a compound according to the invention is understood here as meaning a compound in which at least one atom within the compound according to the invention is exchanged for another atom of the same atomic number but with a different atomic mass than the atomic mass that usually or predominantly occurs in nature.
  • isotopes which can be incorporated into a compound of the invention are those of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), 13 C, 14 C, 15 N, 17 0, 18 0, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 6 Cl , 82 Br, i23 i, 124 f, 129 1 and I3L L
  • Certain isotopic variations of a compound of the invention, in particular those in which one or more radioactive isotopes are incorporated, may be useful, for example, for studying the mechanism of action or of drug distribution in the body; Due to the comparatively easy production and detectability, compounds labeled with 3 H or 14 C isotopes are particularly suitable for this purpose.
  • isotopes such as deuterium may result in certain therapeutic benefits as a result of greater metabolic stability of the compound, such as prolonging the body's half-life or reducing the required effective dose;
  • isotopic variants of the compounds according to the invention can be prepared by the processes known to the person skilled in the art, for example by the methods described below and the rules given in the exemplary embodiments, by corresponding Isotopic modifications of the respective reagents and / or starting compounds can be used.
  • Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. Also included are salts which are themselves unsuitable for pharmaceutical applications but can be used, for example, for the isolation or purification of the compounds of the invention.
  • Physiologically acceptable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid. acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of example, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms.
  • alkali metal salts for example sodium and potassium salts
  • alkaline earth metal salts for example calcium and magnesium salts
  • ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms such as, by way of example and by way of example, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms.
  • Atoms such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylpiperidine, N-methylmorpholine, arginine, lysine and 1,2-ethylenediamine.
  • Solvates in the context of the invention are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water. As solvates, hydrates are preferred in the context of the present invention.
  • the present invention also includes prodrugs of the compounds of the invention.
  • prodrugs refers to compounds which themselves may be biologically active or inactive, but are converted during their residence time in the body to compounds of the invention (for example metabolically or hydrolytically).
  • (C 1 -C 4) -alkyl in the context of the invention represent a linear or branched alkyl radical having 1 to 4 carbon atoms, by way of example and preferably: methyl, ethyl, ⁇ -propyl, isopropyl, ⁇ -butyl, isobutyl, ⁇ -methylpropyl and teri .-Bufyl.
  • Alkanediyl is in the context of the invention a linear, ⁇ , ⁇ -divalent alkyl radical having the particular number of carbon atoms.
  • Examples which may be mentioned by way of example and with preference are: methylene, ethane-1,2-diyl (1,2-ethylene), propane-1,3-diyl (1,3-propylene), butane-1,4-diyl (1,4) Butylene), pentane-l, 5-diyl (1,5-pentylene), hexane-1,6-diyl (1,6-hexylene), heptane-l, 7-diyl (1,7-hexylene), octane l, 8-diyl (1,8-octylene), nonane-l, 9-diyl (1,9-nonylene), decane-l, 10-diyl (1, 10-decylene).
  • CyCTl-cycloalkyl or 3- to 7-membered carbocycle in the context of the invention stands for a monocyclic, saturated cycloalkyl group having 3 to 7 carbon atoms and may be mentioned by way of example and preferably: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • the side group of a q-amino acid in the meaning of R 19 comprises both the side groups of the naturally occurring ⁇ -amino acids and the side groups of homologues and isomers of these ⁇ -amino acids.
  • the ⁇ -amino acid can be present in both the L and the D configuration or else as a mixture of the L and D form.
  • side groups which may be mentioned are: methyl (alanine), propan-2-yl (valine), propan-1-yl (norvaline), 2-methylpropan-1-yl (leucine), 1-methylpropane-1-ylyl ( Isoleucine), butan-1-yl (norleucine), ferric butyl (2-heptabutylglycine), phenyl (2-phenylglycine), benzyl (phenylalanine), p-hydroxybenzyl (tyrosine), indole-3 ylmetyl (tryptophan), imidazol-4-ylmethyl (histidine), hydroxymethyl (serine), 2-hydroxyethyl (homoserine), 1-hydroxyethyl (threonine), mercaptomethyl (cysteine), methylthiomethyl (S-methylcysteine), 2- Mercaptoeihyl (homocysteine), 2-methylthioethyl (methionine),
  • Preferred ⁇ -amino acid side-groups in the meaning of R 1 " are methyl (alanine), propan-2-yl (valine), 2-methylpropan-1-yl (leucine), benzyl (phenylalanine), imidazole-4 -ylmethyl (histidine), hydroxymethyl (serine), 1-hydroxyethyl (threonine), 4-aminobutan-1-yl (lysine), 3-aminopropan-1-yl (ornithine), 2-aminoethyl (2,4-diaminobutyric acid) , Aminomethyl (2,3-diaminopropionic acid), 3-guanidinopropan-1-yl (arginine), in each case the L-configuration is preferred.
  • a 4- to 7-membered heterocycle represents in the context of the invention a monocyclic, saturated heterocycle having a total of 4 to 7 ring atoms, which contains one or two ring heteroatoms from the series, O, S, SO and / or SO 2 and is linked via a ring carbon atom or optionally a ring nitrogen atom - to 7-membered heterocycle having one or two ring heteroatoms from the series N, O and / or S, particularly preferably a 5-membered or 6-membered heterocycle having one or two Ri
  • examples include: azetidinyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, thiolanyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, polypholinyl, thiomorpholinyl, hexahydroazepinyl and
  • radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. Substitution with one or two identical or different substituents is preferred. Particularly preferred is the substitution with a substituent.
  • linker is broadly understood to mean a chemical entity comprising a covalent bond or an array of atoms that covalently attaches a binder to an agent, Preferably, the term “linker” is used as an array of atoms in the sense of Understand the present invention, which covalently attaches a binder to a drug.
  • linkers may be, for example, divalent chemical moieties such as alkyldiyls, aryldiyls, heteroaryldyls, heterocyclyldyls, dicarbonylic acid esters, dicarbonylic acid amides.
  • binder is broadly understood to mean a molecule that binds to a target molecule present on a particular target cell population to be targeted with the binder-drug conjugate includes, for example, lectins, proteins capable of binding certain sugar chains, or phospholipid-binding proteins, such as, for example, high molecular weight proteins (binding proteins), polypeptides or peptides (binding peptides), non-peptidic (eg, aptamers (US5,270,163) (review articles) Rev.
  • lectins proteins capable of binding certain sugar chains
  • phospholipid-binding proteins such as, for example, high molecular weight proteins (binding proteins), polypeptides or peptides (binding peptides), non-peptidic (eg, aptamers (US5,270,163) (review articles) Rev.
  • Binding proteins are eg antibodies and antibody fragments or such as Affibodies, Adnectins, Anticalins, DARPins, Avimers, Nanobodies (reviewed by Gebauer M. et al., Curr. Opinion in Chem. Biol. 2009; 13: 245-255; Nuttall SD et al., Curr. Opinion in Pharmacology 2008; 8: 608-617).
  • Binding peptides are, for example, ligands of a ligand-receptor pair, such as VEGF of the ligand-receptor pair VEGF / KDR, such as transferrin of the ligand receptor pair Transferrin Traiisferriii receptor or cytokine / cytokine receptor, such as TNF alpha of the ligand receptor pair TNFalpha 'TNFalpha receptor.
  • ligands of a ligand-receptor pair such as VEGF of the ligand-receptor pair VEGF / KDR
  • transferrin of the ligand receptor pair Transferrin Traiisferriii receptor or cytokine / cytokine receptor, such as TNF alpha of the ligand receptor pair TNFalpha 'TNFalpha receptor.
  • Preferred binders according to the invention are (in particular human, monoclonal) antibodies or antigen-binding antibody fragments which bind to C4.4a, in the case of anti-C4.4a antibodies n, ie the number of toxophore molecules per antibody molecule, is preferably in the range from 1 to 10, more preferably 2 to 8.
  • a “target molecule” is broadly understood to be a molecule present in the target cell population, and may be a protein (eg, a growth factor receptor) or a non-peptidic molecule (eg, a sugar or phospholipid)
  • the term "extracellular" target molecule describes a cell-bound target molecule located on the outside of a cell, or the part of a target molecule that is on the outside of a cell, ie, a binder can bind to an intact one Bind cell to its extracellular target molecule.
  • An extracellular targeting molecule may be anchored in the cell membrane or be part of the cell membrane.
  • the person skilled in the art knows methods to identify extracellular target molecules. For proteins, this can be done by determining the transmembrane domain (s) and the orientation of the protein in the membrane. This information is usually stored in protein databases (eg SwissProt).
  • cancer target molecule describes a target molecule that is more abundant on one or more types of cancer cells as compared to non-cancerous cells of the same tissue type, Preferably, the cancer target molecule is on one or more cancer cell types compared to non-cancerous cells of the same Tissue type selectively present, selectively delineating at least two-fold accumulation on cancer cells compared to non-cancer cells of the same tissue type (a "selective cancer target molecule”).
  • selective cancer target molecule allows the selective therapy of cancer cells with the conjugates of the invention.
  • the binder can be linked via a linkage with the linker.
  • linkage of the binder can be effected by means of a heteroatom of the binder.
  • Heterocycles of the invention that can be used for linking are sulfur (in one embodiment via a sulthydryl group of the binder), oxygen (according to the invention by means of a carboxyl or hydroxyl group of the binder) and nitrogen (in one embodiment via a primary or secondary amine group or atnide group of the Binders).
  • Preferred according to the invention is the conjugation of the toxophore to the antibody via one or more sulfur atoms of cysteine residues of the antibody and or via one or more NH groups of lysine residues of the antibody.
  • These heating atoms may be present in the natural binder or introduced by chemical or molecular biological metliodes.
  • the linkage of the binder with the toxophore has only a small influence on the binding activity of the binder to the target molecule. In a preferred embodiment, the linkage has no influence on the binding activity of the binder to the target molecule.
  • an immunoglobulin molecule preferably comprises a molecule having four polypeptide chains, two heavy chains (H chains) and two light chains (L chains), which are typically linked by disulfide bridges.
  • Each heavy chain comprises a heavy chain variable domain (abbreviated VH) and heavy chain constant domain.
  • the heavy chain constant domain may include three domains CHI, CH2 and CH3.
  • Each light chain comprises a variable domain (abbreviated VL) and a constant domain.
  • the constant domain of the light chain comprises a domain (abbreviated to CL).
  • the VH and VL domains can be further subdivided into regions of hypervariability, also called complementarity determining regions (abbreviated to CDR) and regions of lower sequence variability (FR).
  • CDR complementarity determining regions
  • FR regions of lower sequence variability
  • Each VH and VL region typically consists of three CDRs and up to four FRs.
  • FRi complementarity determining regions
  • An antibody can be obtained from any suitable species, eg, rabbit, llama, camel, mouse, or rat. In an execution form! the antibody is of human or murine origin.
  • An antibody may be, for example, human, humanized or brain.
  • the term “monoclonal” antibody refers to antibodies obtained from a population of substantially homogeneous antibodies, ie, individual antibodies of the population are identical except for naturally occurring mutations which can occur in small numbers.Monoclonal antibodies recognize with high specificity a single antigenic binding site The term “monoclonal antibody” does not refer to any particular method of production.
  • the term “intact” antibody refers to antibodies comprising both an antigen-binding domain and the light and heavy chain constant domain.
  • the constant domain may be a naturally occurring domain, or a variant thereof in which one or more amino acid positions have been altered.
  • modified intact antibody refers to intact antibodies fused to another non-antibody polypeptide or protein via their amino terminus or carboxy-terminus via a covalent bond (eg, a peptide linkage) modified to introduce reactive cysteines at defined sites to facilitate coupling to a toxophore (see Junutula et al., Nat Biofechnol., 2008 Aug; 26 (8) i925-32).
  • human antibody refers to antibodies that can be obtained from a human or that are synthetic human antibodies
  • a "synthetic" human antibody is an antibody that is available in part or in whole from synthetic sequences in silico that have been analyzed based on human antibody sequences.
  • a human antibody may be encoded by a nucleic acid isolated from a library of antibody sequences of human origin. An example of such antibodies is in Söderlind et al., Ature Biotech. 2000, 18: 853-856.
  • humanized or “chimeric” antibody describes antibodies consisting of a non-human and a human sequence portion. In these antibodies, part of the sequences of the human immunoglobulin (recipient) is replaced by sequence portions of a non-human immunoglobulin (donor).
  • the donor is a murine immunoglobulin in many cases.
  • amino acids of the CDR of the recipient are replaced with amino acids of the donor. Sometimes amino acids of the framework are replaced by corresponding amino acids of the donor.
  • the humanized antibody contains amino acids that were not contained in either the recipient or the donor and that would be inserted during optimization of the antibody.
  • the variable domains of the donor immunoglobulin, or even the entire Fab fraction, ie VL-CL and VII + CHI are fused to the constant regions of a human antibody.
  • complementarity determining region refers to those amino acids of a variable antibody domain necessary for binding to the antigen.
  • Each variable region typically has three CDR regions, referred to as CDR1, CDR2 and CDR3.
  • Each CDR region may comprise amino acids as defined by Kabat and / or amino acids of a hypervariable loop defined by Chotia.
  • the Kabat definition includes, for example, the region of approximately amino acid position 24-34 (CDR1), 50-56 (CDR2) and 89-97 (CDR3) of the variable light chain and 31-35 (CDR1), 50-65 (CDR2).
  • CDR3 variable heavy chain Kabat et al., Sequences of Proteins of Immulological Filter, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)).
  • the definition according to Chotia includes the region of approximately amino acid position 26-32 (CDR1), 50-52 (CDR2) and 91-96 (CDR3) of the variable light chain and 26 32 (CDR1), 53-55 (CDR2) and 96 101 (CDR3) of the variable heavy chain Chothia and Lesk; J Mol Biol 196: 901-917 (1987)).
  • a CDR may comprise amino acids from a CDR region as defined by Kabat and Chotia.
  • antibodies can be grouped into different classes. There are five major classes of intact antibodies: IgA, IgD, IgE, IgG and IgM, several of which can be broken down into other subclasses. (Isotypes), eg IgGl, IgG2, IgG3, TgG4, TgAl and IgA2.
  • the heavy chain constant domain corresponding to the different classes are referred to as [alpha / a], [delta / ⁇ ], [epsilon / ⁇ ], [garnma / ⁇ ] and [my / ⁇ ]. Both the three-dimensional structure and the subunit structure of antibodies are known.
  • the term "functional fragment” or "antigen-binding antibody fragment” of an antibody / immunoglobulin is defined as a fragment of an antibody / immunoglobulin (eg, the variable domains of an IgG) which still comprises the antigen binding domains of the antibody / immunoglobulin
  • Antigen binding domain typically comprises one or more hypervariable regions of an antibody, eg the CDR1, CDR2 and / or CDR3 region.
  • the "framework” or “framework” region of an antibody may also play a role in binding the antibody to the antigen.
  • the framework region provides the framework for the CDRs.
  • the antigen-binding domain comprises at least amino acids 4 to 103 of the variable light chain and amino acids 5 to 109 of the variable heavy chain, more preferably amino acids 3 to 107 of the variable light chain and 4 to 111 of the variable heavy chain, most preferably the complete ones variable light and heavy chains, ie amino acid 1 109 of the VL and 1 to 113 of the VH (numbering according to WO97 / 08320).
  • “Functional fragments” or “antigen-binding antibody fragments” of the invention do not exhaustively include Fab, Fab ', F (ab') 2 and Fv fragments, diabodies, single domain antibodies (DAbs), linearae antibodies, single chain antibodies (single-chain Fv , abbreviated scFv); and multispecific, such as bi- and tri-specific, antibodies formed from antibody fragments CA K Borrebaeck, editor (1995) Antibody Engineering (Breakthroughs in Molecular Biology), Oxford University Press; R. Kontermann & S. Duebel, editors (2001) Antibody Engineering (Springer Laboratory Manual), Springer Verlag). Antibodies other than "multi-specific” or “multi-functional” are those with identical binding sites.
  • Multispecific antibodies may be specific for different epitopes of an antigen or specific for epitopes of more than one antigen (see eg WO93 / 17715, WO92 / 08602, WO91 / 00360, WO92 / 05793, Tuti, et al., 1991, J. Immunol., 147: 60 69; U.S. Patent Nos. 4,474,893; 4,7 14,68 1; 4,925,648; 5,573,920; 5,601,819; or Kostelny et al., 1992, J. Immunol. 148: 1547 1553). , An F (from ').
  • Fab molecule can be engineered to reduce or completely prevent the number of intermolecular disulfide interactions that occur between the Chi and CL domains.
  • “Functional fragments” or “antigen-binding antibody fragments” may be fused to another non-antibody polypeptide or protein via their amino-terminus or carboxy-terminus via a covalent bond (eg, a peptide linkage).
  • you can and antigen-binding fragments are modified to introduce reactive cysteines at defined sites to facilitate coupling to a toxophore (see Junutula et al., Nat Biotechnol., 2008 Aug; 26 (8): 925-32),
  • Polyclonal antibodies can be prepared by methods known to those of ordinary skill in the art.
  • Monoclonal antibodies can be prepared by methods known to those of ordinary skill in the art (Köhler and Milstein, Nature, 256, 495-497, 1975).
  • Humanized human monoclonal antibodies can be prepared by methods known to those of ordinary skill in the art (Olsson et al., Meth Enzymol., 92, 3-16 and Cabilly et al., US 4,816,567 or Boss et al US 4,816,397).
  • Candidates of the invention may be recombinant
  • Antibodies made up of a large number of healthy volunteers can also be made by known recombinant DNA technology. The
  • Nucleic acid sequence of an Andlauer can be obtained by routine sequencing, or is available from publicly available databases.
  • an "isolated" antibody or binder has been purified from other components of the cell Contaminating components of a cell which may interfere with a diagnostic or therapeutic use are, for example, enzymes, hormones, or other peptidic or non-peptidic components of a cell an amino acid or binder which has been purified to more than 95% by weight, based on the antibody or binder (determined, for example, by Lowry method, UV-Vis spectroscopy or by SDS capillary gel electrophoresis), which has been purified to the extent that at least 15 amino acids of the amino terminus or an internal amino acid sequence can be determined or purified to homogeneity, the homogeneity being determined by SDS-PAGE under reducing or non-reducing conditions (the detection can be determined by Coomassie blue staining or preferably by silver staining).
  • a ⁇ ⁇ becomes normal ise prepared by one or more purification steps.
  • the term "specific binding” or “specific binding” refers to an antibody or binder that binds to a predetermined antigen / target molecule.
  • Specific binding of an antibody or binder typically describes an antibody or binding with an affinity of at least 10 "7 M (as Kd value, so preferably those with smaller Kd values than lO"'7 M), wherein the antibody or binder has at least two-fold higher affinity for the predetermined antigen / target molecule than for a non-specific antigen / target molecule (eg, bovine serum albumin, or casein) which is not the predetermined antigen / target molecule or a closely related antigen / target molecule.
  • a non-specific antigen / target molecule eg, bovine serum albumin, or casein
  • Antibodies specific for a cancer cell antigen may be prepared by those of ordinary skill in the art by methods known to those skilled in the art (such as recombinant expression) or may be purchased commercially (e.g., from Merck KGaA, Deustchland). Examples of known commercially available antibodies in cancer therapy are Erbitux® (Cetuximab, Merck KGaA), Avastin® (Bevacizumab, Roche) and Herceptin® (Trastuzumab, Genentech).
  • the antibody is produced recombinantly in CHO cells.
  • the compounds of the formula (i) represent a subgroup of the compounds of the formula (Ia).
  • Preferred subject matter of the invention are binder-active compound conjugates of the general formula (Ia) in which n is a number from 1 to 50,
  • AK for AK. or AK 2 represents
  • AK. for a binder (preferably an anti-C4.4a antibody) bound to the group G via a sulfur atom of the binder preferably an anti-C4.4a antibody bound to the group G via a sulfur atom of the binder
  • n is a number from 2 to 6
  • ## 5 denotes the point of attachment to the group G
  • L ' A is linear (C 2 -C 10) -alkanediyl.
  • R 33 is hydrogen, (C 1 -C 4) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
  • R 34 is hydrogen or methyl
  • R 29 is hydrogen or (C 1 -C 4) -alkyl
  • R 30 is hydrogen or (C 1 -C 4) -alkyl, or R 30 together with the atoms to which they are attached form a 5- or 6-membered heterocycle, R 31 is hydrogen or (Ci-G alkyl, R 32 is hydrogen or (Ci-C4) alkyl, or
  • R 3 'and R 3 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • L ' B is linear (Ci-Cicj alkandivl, and wherein (Ci-Cio) alkanediyl may be substituted with 1 to 4 substituents independently selected from the group consisting of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl chain in 1, 2, 1, 3 or 1, 4 relation to each other, including the carbon atoms optionally between them can be bridged to a (Cs-Cej-cycloalkyl ring or a phenyl ring, for a bond or a group the formula
  • the point of attachment is L 1
  • the point of attachment is L 2 , O or NH.
  • L 3 is a bond or (C 2 -C 4 -alkanediyl.
  • L 4 represents a bond or a group of the formula
  • point of attachment to the carbonyl group is characterized. denotes the point of attachment to L 2 , is hydrogen or methyl.
  • R is hydrogen, (C 1 -C 4 ) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
  • Q 1 represents a 4- to 7-membered heterocycle
  • Q 2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle
  • R 14 is hydrogen or (Ci-C 4 ) -alkyl
  • R ! 5 represents hydrogen or (C 1 -C 4 ) -alkyl
  • R 14 and R 13 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • R 16 represents hydrogen or (C 1 -C 4 ) -alkyl
  • R 17 is hydrogen or (Ci-C 4 ) -alkyl, or
  • R 16 and R 17 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • R 18 is hydrogen or (C 1 -C 4) -alkyl
  • R 19 represents hydrogen or the side group of a natural ⁇ -amino acid or its homologs or isomers
  • R 20 is hydrogen or (C 1 -C 4 ) -alkyl, or
  • R 21 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 22 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 23 represents (Ci-CVi-alkyl
  • R 24 is hydrogen or (C 1 -C 4) -alkyl
  • R 27 is hydrogen or C 1 -C -alkyl
  • R j6 represents hydrogen, (C 1 -C 4) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
  • R 37 is hydrogen or methyl
  • L 2 is linear (C 2 -C 10) -alkanediyl or a group of the formula where p is a number from 2 to 6,
  • ## 3 denotes the point of attachment to the group B
  • (C 2 -C 10) -alkanediyl having 1 to 4 substituents independently of one another can be substituted from the group consisting of methyl, hydroxy and benzyl, and where two carbon atoms of the alkanediyl chain are in 1, 2, 1, 3 or 1 , 4-relative to one another, including the optionally located between them Kohienstoffatome to a (C3-C6) -Cycloa31cyi ring or a phenyl ring may be bridged,
  • R 2 is Tsopropyl, isobutyl, ⁇ -butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenyl ethyl, diphenylmethyl, 1H-lxiidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
  • # 5 denotes the point of attachment with the Carbonyi group, the ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
  • R ' is hydrogen, hydroxy or benzyloxy, is hydrogen or methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1 - Phenyl ethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1/7-indol-3-ylmethyl,
  • # 8 identifies the point of attachment to the group T 1 .
  • R ? represents hydrogen, methyl, ethyl, w-propyl, tert-butyl, benzyl or adamantylmetyl
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i0 is benzoyl.
  • R u for benzyl which may be substituted in the phenyl group with methoxyearbonyi or carboxyl, is hydrogen, methyl or a group of the forms! stands in which
  • # 9 identifies the point of attachment with -CHC (R 26 ) -T 2 ,
  • R '' ' is phenyl, which may be substituted by methoxyearbonyi, carboxyl or a group of the formula -S (O):> OH,
  • R is phenyl which may be substituted with methoxyearbonyi or carboxyl
  • R 26 is hydrogen or hydroxy
  • T 2 is pbenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are binder-active compound conjugates of the general formula (Ia) as indicated above, in which n is a number from 1 to 50,
  • AK for AK or ⁇ K wherein for a binder (preferably a anfi-C4.4a Amik bound via a sulfur atom of the binder to the group G, AK 2 for a binder (preferably an anti-C4.4a antibody) which is bound to the group G via a nitrogen atom of the binder,
  • n is a number from 2 to 6.
  • ## 1 denotes the point of attachment to the gib G
  • L iA is linear (C-2-Cio) -alkanediyl
  • R 33 is hydrogen, (C 1 -C 4) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
  • R 34 is hydrogen or methyl
  • R 29 is hydrogen or (C 1 -C 4) -alkyl
  • R 30 is hydrogen or (C 1 -C 4) -alkyl, or R 30 together with the atoms to which they are attached form a 5- or 6-membered heterocycle, R 31 is hydrogen or (Ci-G alkyl, R 32 is hydrogen or (Ci-C4) alkyl, or
  • R 31 and R 3 together with the atoms to which they are attached form a 5- or 6-membered heterozygus
  • L lB is linear (Ci-Ciöj alkanediyl, and wherein (Ci-Cio) -Alkandiyi may be substituted with 1 to 4 substituents independently selected from the group consisting of methyl, Hydroxv and benzyl, and wherein two carbon atoms of the alkanediyl chain in 1, 2, 1, 3 or 1, 4 relative to each other, with the inclusion of any carbon atoms between them may be bridged to a (Cs-Cej-Cycioalkyl ring or a phenyl ring, a bond or a group of Fonnel
  • L 3 represents a bond or (C 1 -C 6 -alkanediyl
  • L 4 represents a bond or a group of the formula
  • R 25 is hydrogen or methyl
  • R 28 is hydrogen, (C 1 -C 4) -alkylcarbonyi, tert-butyloxycarbonyl or benzyloxycarbonyl,
  • Q 1 is a 4- to 7-membered heterocycle
  • Q 2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle
  • R 14 is hydrogen or (C 1 -C 4 -alkyl
  • R 15 is hydrogen or (Ci-C 4 ) -alkyl, or
  • R 14 and R 13 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • R 16 is hydrogen or
  • R 17 is hydrogen or (C 1 -C 4 ) -alkyl, or
  • R 18 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 19 is hydrogen or the side group of a natural ⁇ -amino acid or its
  • R 20 is hydrogen or (C 5 -C) alkyl, or
  • R 2 ' is hydrogen or (C 1 -C 4) -alkyl
  • R 22 is hydrogen or (Ci-C4) alkyl, or
  • R zl and R z2 together with the atoms to which they are attached form a 3- to 7-membered carbocycle
  • R 23 is (C 1 -C 4 ) -alkyl
  • R 24 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 27 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 36 represents hydrogen, (C 1 -C 4 ) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
  • R ,? is hydrogen or methyl
  • ## 3 denotes the point of attachment to the group B
  • R ! is hydrogen or methyl
  • R 1 is isopropyl, isobutyl, sec-butyl, fö / t-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenyl ethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
  • # 4 denotes the point of attachment to the adjacent nitrogen atom
  • # 5 denotes the point of attachment to the carbonyl group
  • ring A contains the NO group contained therein for a monocyclic or bicyclic, optionally substituted heterocycle of the formula
  • R 6 is hydrogen, hydroxy or benzyloxy
  • R J is hydrogen or methyl
  • R 4 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl, Diphenylmethyl, 1H-imidazol-4-ylmethyl or 1/7-indol-3-ylmethyl, or
  • R 7 is hydrogen, methyl, ethyl, w-propyl, tert-butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i0 is benzoyl
  • R ' 1 for benzyl which may be substituted in the Phenyignippe with methoxycarbonyl or carboxyi, is hydrogen, methyl or a group of the formula
  • R 12 is phenyi which may be substituted by methoxycarbonyl, carboxy or a group of the formula -S (O) 20H,
  • R ' 3 is phenyi which may be substituted with methoxycarbonyl or carboxyi
  • R zo is hydrogen or hydroxy
  • T 2 is phenyi, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the invention are B in the active substance Koniugate of the general formula (Ia), in which n is a number from 1 to 20, AK for AK, or AK 2 is
  • AK- for an antibody or an antigen-binding antibody fragment which binds to C4,4a and is bound to the group G via the sulfur atom of a cysteine residue of the binder
  • AK.2 for an antibody or an antigen sees binding anii Economicsfragrneni which binds to C4.4a and is bound via the NH side group of a lysine residue of the binder to the group G
  • AK AKi
  • n is a number from 2 to 6
  • L iA stands for linear (CVCej alkandiy!
  • ## 7 denotes the point of attachment with the carbonyl group
  • ## 8 denotes the point of attachment to LIB
  • R J is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
  • R 34 is hydrogen or methyl
  • R 29 is hydrogen
  • R 30 is hydrogen
  • R 31 is hydrogen or methyl
  • R 32 is hydrogen or methyl
  • L 3 is a bond or ethane-l, 2-diyl
  • R 25 is hydrogen or methyl
  • R 28 is hydrogen, methylcarbonyl or iert.-butyloxycarbonyl
  • Q ' is a 4- to 7-membered heterocycle
  • R 14 is hydrogen
  • R 15 is hydrogen
  • R 16 is hydrogen or methyl
  • R 17 is hydrogen or methyl
  • R 18 is hydrogen
  • R 19 is hydrogen, methyl, propan-2-yl, 2-methylpropan-1-yl or 1-methylpropan-1-yl,
  • R 20 is hydrogen or methyl
  • R 2i is hydrogen or methyl
  • R 2 is hydrogen or methyl, or
  • R 24 is hydrogen or methyl
  • R 27 is hydrogen
  • R 36 is hydrogen, methylearbonyl or tert-butyloxycarbonyl
  • R looks for hydrogen or methyl, or R 36 and R 37 , together with the atoms to which they are attached form PyiTolidinring, linear (C 2 -C 6) alkanediyl or a group of the formula where p is a number from 2 to 6,
  • ## 3 denotes the point of attachment to the group B
  • R 1 is hydrogen
  • R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybeiizyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
  • # 4 identifies the linkage site with the adjacent nitrogen atom
  • # 5 identifies the linkage site with the carbonyl group, the ring A with the NO moiety contained therein for a monocyclic or bicyclic, optionally substituted heterocycle of the formula
  • # ö denotes the point of attachment to the carbonyl group
  • R 6 represents hydrogen, hydroxyl or benzyloxy
  • R 3 is hydrogen
  • R 4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl.
  • R 7 is hydrogen, methyl, ethyl, w-propyl, tert-butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i0 is benzoyl
  • R ' 1 for benzyl which may be substituted in the phenyl group with methoxycarbonyl or carboxyi, is hydrogen, methyl or a group of the formula
  • R 12 is phenyi, that with methoxycarbonyl, carboxyi or a group of the forms! -S (0) 20H can be substituted,
  • R ' 3 is phenyi which may be substituted with methoxycarbonyl or carboxyi
  • R zo is hydrogen or hydroxy
  • T 2 is phenyi, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are binder-active compound conjugates of the general formula (Ia) as indicated above, in which n represents a number from 1 to 20, AK represents AK, or AK 2 represents
  • AK- for an antibody or an antigen-binding antibody fragment which binds to C4,4a and is bound to the group G via the sulfur atom of a cysteine residue of the binder
  • m is a number from 2 to 6, which indicates the point of attachment to the group G,
  • V stands for a bond
  • L 6 represents a bond or a group of the formula
  • ## 7 denotes the point of attachment with the carbonyl group
  • ## 8 denotes the point of attachment to LIB
  • R J is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
  • R 34 is hydrogen or methyl
  • R 29 is hydrogen
  • R 30 looks for hydrogen
  • R 31 is hydrogen or methyl
  • R 32 is hydrogen or methyl
  • L 1B is linear (C 2 -C 6) -alkanediyl
  • L 3 is a bond or ethane-l, 2-diyl
  • L 4 represents a bond or a group of the formula
  • R 25 is hydrogen or methyl
  • R 28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
  • Q 1 is a 4- to 7-membered heterocycle
  • R 14 is hydrogen
  • R ! 5 is hydrogen
  • R 16 is hydrogen or methyl
  • R ' 7 is hydrogen or methyl
  • R 19 is hydrogen, methyl, propan-2-yl, 2-methylpropan-1-yl or 1-methylpropan-1-yl,
  • R 20 is hydrogen or methyl
  • R 21 is hydrogen or methyl
  • R 22 is hydrogen or methyl
  • R 24 is hydrogen or methyl
  • R 27 is hydrogen
  • R 36 is hydrogen, (C 1 -C 4) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl, R 37 is hydrogen or methyl.
  • R 1 is hydrogen
  • R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
  • # 4 identifies the linkage site with the adjacent nitrogen atom
  • # 5 identifies the linkage site with the carbonyl group, the ring A with the NO moiety contained therein for a monocyclic or bicyclic, optionally substituted heterocycle of the formula
  • # ö denotes the point of attachment to the carbonyl group
  • R 6 represents hydrogen, hydroxyl or benzyloxy
  • R 3 is hydrogen
  • R 4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl.
  • R 7 is hydrogen, methyl, ethyl, w-propyl, tert-butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i0 is benzoyl
  • R ' 1 for benzyl which may be substituted in the Phenyigi'uppe with methoxycarbonyl or carboxyi, is hydrogen, methyl or a group of the formula
  • R 12 is phenyl which may be substituted by methoxycarbonyl, carboxyl or a group of the formula -S (0) 2 0H,
  • R ' 3 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
  • R zo is hydrogen or hydroxy
  • T 2 represents phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl
  • R J5 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred object of the invention are binder active ingredient Koniugate of the general formula (fa), in which n is a number from 1 to 10, AK for AKi or AK 2 is
  • AK- for an antibody containing the six CDR sequences of the antibody B0I -3, B01-10, M31-B01 or D02-6, the variable light and variable heavy chain of the antibody B01-3, B01-10, M31 - B01 or D02-6 or the light and heavy chain of the antibody B01-3, B01 -10, M31-B01 or D02-6, which is bound via the sulfur atom of a cysteine residue of the binder to the group G,
  • L 1 represents a bond, linear (CVChj-alkanediyl, a group of formula where m is a number of 2 or 3,
  • ## 5 denotes the point of attachment to the group G
  • L 3 is a bond or ethane-l, 2-diyl.
  • L 4 represents a bond or a group of the formula
  • R 25 is methyl
  • Q 1 is piperidine-1, 4-diyl, R 16 is hydrogen or methyl, R ! 7 is hydrogen or methyl, or
  • R 2 is hydrogen or meth l
  • R 22 is hydrogen or methyl
  • R 23 is methyl
  • R 24 is hydrogen
  • R 3! is hydrogen, methylcarbony] or tert-butyloxycarbonyl
  • R 37 is hydrogen or methyl
  • L 2 is linear (Ci-Cel-alkanediyl or a group of the formula
  • ## 3 denotes the point of attachment to the group B
  • R 1 is hydrogen
  • R is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-yl-methyl, or 1 and R 2 together with the carbon atom to which they are attached form a
  • # 5 denotes the point of attachment with the carbonyl group, the ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula wherein the point of attachment to the carbonyl group is hydrogen, hydroxy or benzyloxy.
  • R ! stands for hydrogen
  • R 4 is benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, above
  • R ' is hydrogen, methyl, ethyl, r-propyl, tert-butyl, benzyl or adamantvlmethvl
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, propyl or benzyl
  • R 1 is benzyl which may be substituted in the phenyl group by methoxyearbonyl or carboxyl,
  • R 5 is hydrogen, methyl or a group of the formula stands in which
  • # 9 identifies the linkage position with -CHCEfePhenyl
  • R ' 2 stands for Phenvl, which with methoxyearbonyl, carboxyl or a group of the forms! -S (0) 2 0H can be substituted
  • R is phenyl which may be substituted with methoxyearbonyl or carboxyl
  • R is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are binder-active compound conjugates of the general formula (Ia) as indicated above, in which n is a number from 1 to 10,
  • AK for AK. or AK 2 represents
  • AKi for an antibody comprising the six CDR sequences of the antibody B01-3, B01-10, M31-B01 or D02-6, the variable light and variable heavy chain of the antibody B01-3, B01-10, M31-B01 or D02-6 or the light and heavy chain of the antibody B01-3, B01 -10, M31 -B01 or D02-6, which is bound via the Scliwefeiatom a Cvstein residue of the binder to the group G
  • L 3 looks for a bond or ethane-1, 2-diyl
  • R 25 is methyl
  • R 28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl, Q 1 is piperidin-1,4-diyl,
  • R ! 6 is hydrogen or methyl
  • R 17 is hydrogen or methyl
  • R 2i is hydrogen or methyl
  • R 22 is hydrogen or methyl
  • R i4 is hydrogen, linear (Ca-CeVAikandiyl or a group of the formula where p is a number from 2 to 6,
  • R ' is hydrogen
  • R z is 1-hydroxyethyl, benzyl, ⁇ -hydroxybenzyl, 1-phenylethyl or 1/7-indol-3-yl methvl, ocier
  • R is hydrogen, hydroxy or benzyloxy
  • R 3 is hydrogen
  • R 4 is benzyl, 1-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or R J and R 4 together with the carbon atom to which they are attached form a (15,2R) -2-phenylcyclopropane-1,1-diyl group of the formula
  • R 7 is hydrogen, methyl, ethyl, propyl, tert. Butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, propyl or benzyl
  • R ' 1 for benzyl which may be substituted in the phenyl group with methoxycarbonyl or carboxyi, is hydrogen, methyl or a group of the formula in which the linking parts are denoted by -CHCtbPhenyl, is phenyl which may be substituted by methoxycarbonyl, carboxy or a group of the formula -SiOj OH, R ' 3 is phenyl which may be substituted by methoxy-carbonyl or carboxyl,
  • R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are binder-active compound conjugates of general formula (Ia) as indicated above, in which n is a number from 1 to 10,
  • AK stands for AK 2 , where
  • AK.2 for an antibody comprising the six CDR sequences of the antibody BO1-3, B01-10, M31-B01 or D02-6, the variable light and variable heavy chain of the antibody B01-3, B01-10, M31 B01 or D02-6 or the light and heavy chain of the Anügropers BOI-3, B01 -10, M31-B01 or D02-6 comprises, which is bound via the NH side group of a lysine residue of the binder to the group G. .
  • G is carbonyl
  • B is a bond, linear (Ca-Cej alkanediyl or a group of the formula
  • R 1 is hydrogen
  • R 2 is benzyl or 1H-indol-3-ylmethyl
  • # 5 denotes the point of attachment to the carbonyl group, the ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted Heierocyclus of the formula
  • R 3 is hydrogen
  • R 4 is benzyl or 1H-indol-3-ylmethyl, or
  • R 7 is hydrogen, methyl, ethyl, w-propyl, tert-butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen
  • R 9 is hydrogen or benzyl
  • R is methyl. and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are binder-active compound conjugates of the general formula (Ia) as indicated above, in soft n is a number from 1 to 10,
  • AK stands for AK2, where
  • G is carbonyl
  • V stands for a bond
  • ## 3 denotes the point of attachment to the group B
  • R 2 is 4-hydroxybenzyi or 1 // - Tndol-3-ylmethyl, or
  • # 5 denotes the linking moieties with the carbonyl group, the ring A with the NO moiety contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
  • R 3 is hydrogen
  • R 4 is 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or R J and R 4 together with the carbon atom to which they are attached form a (1S, 2R) -2-phenylcyclopropane ⁇ , 1-diyl group of the formula
  • R 7 is hydrogen, methyl, F, ethyl, propyl, tert-butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen
  • R 9 is hydrogen or benzyl
  • R 35 is methyl, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are binder-active compound conjugates of the general formula (Ia) as indicated above, in which n is a number from 1 to 10,
  • AK for an antibody containing the six CDR sequences of the antibody BOl -3, B01-10, M31-B01 or D02-6, the variable light and variable heavy chain of the antibody Antibody B01-3, BOI -10, M31-B01 or D02-6 or the light and heavy chain of the antibody B01-3, BOI-10, M31-B01 or D02-6, which is linked via the sulfur atom of a cysteine Restes of the binder is bound to the group G, for a group of the formula
  • # 2 denotes the point of attachment to the group L ', a bond, linear (C3-C5) alkanediyl or a group of the formula where m is a number of 2 or 3,
  • L 3 is a bond or ethane-1, 2-diyl
  • L 4 is a bond or a group of the formula
  • R z8 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl, R li! is hydrogen or methyl,
  • R 1 ' is hydrogen or methyl
  • R 1 is hydrogen
  • R 2 is benzyl or 1H-indol-3-ylmethyl
  • # 5 denotes the point of attachment to the carbonyl group, the ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted Heierocyclus of the formula
  • R 3 is hydrogen
  • R 4 is benzyl or 1H-indol-3-ylmethyl
  • R is hydrogen
  • R 9 is hydrogen or benzyl
  • R 35 is methyl, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are binder-active conjugates of the general Fonnei (la) as indicated above, in soft n is a number from 1 to 1 0,
  • AK stands for AKi, where
  • AKi for an antibody containing the six CDR sequences of the antibody B01-3, BOi-K ) , M31-B01 or D02-6, the variable light and variable heavy chain of the antibody B01-3, B01 -10, M31 - B01 or D02-6 or the light and heavy chain of the antibody B01 -3, BOl -10, M31-B01 or D02-6 urnankt, which is bound via the sulfur atom of a cysteine residue of the binder to the group G.
  • G is a group of the formula
  • tt denotes the point of attachment with the group L 1 , for a bond, linear (C 3 -C 5) -alkanediyl or a group of the formula where m is a number of 2 or 3,
  • ## 1 denotes the point of attachment to the group G which identifies the point of attachment to the group B.
  • (C 3 -C 5) -alkanediyl can be substituted by ⁇ or 2 substituents methyl, for a bond or a group of the formula where the point of attachment is labeled L ', the point of attachment is labeled L 2 ,
  • L- is a bond or ethane-l, 2-diyl, a bond or a group of the formula
  • R 2S is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
  • R li! is hydrogen or methyl
  • R 17 is hydrogen or methyl
  • i denotes the point of attachment to the group B
  • ⁇ denotes the point of attachment to the nitrogen atom
  • R 1 is hydrogen
  • R 2 is 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
  • R 3 is hydrogen
  • R 4 is 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
  • R 7 is hydrogen, methyl, ethyl, w-propyl, tert. Is butyl, benzyi or adamantylmethyl,
  • R 8 is hydrogen, R is hydrogen or benzyl
  • R 35 is methyl, and their salts, solvates and solvates of the salts.
  • Another object of the present invention are compounds of the formula (XXXa)
  • ## 5 denotes the point of attachment to the group G
  • A is linear (C 2 -C 10) -alkanediyl
  • R 29 is hydrogen or (Ci-C4) alkyl
  • R J0 is hydrogen or (Ci-C4) -Alk, or
  • R 29 and R 30 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • R J1 is hydrogen or (Ci-C4) -Alk l,
  • R 32 is hydrogen or (Ci-C- alkyl, or
  • R 31 and R 3i together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • L iB is linear (C 2 -C 10) -alkanediyl, and wherein (C 1 -C 10) -alkanediyl may be substituted with 1 to 4 substituents independently selected from the group of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl Chain in 1, 2, 1, 3, or 1, 4 relation to each other, including the carbon atoms optionally between them can be bridged to a (C3-Ce) -cycloalkyl ring or a phenyl ring, for a bond or a group of the formula
  • L 3 is a bond or (C 2 -C 4 ) -alkanediyl, L 4 is a bond,
  • Q 2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle
  • R 14 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 15 is hydrogen or (C 5 -C) -alkyl
  • R 14 and R 15 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • R ! 6 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 17 is hydrogen or (Ci-C 4 ) -alkyl, or R 16 and R 17 together with the atoms to which they are attached form a 5- or 6-membered heterocycle,
  • R 18 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 19 is hydrogen or the side group of a natural ⁇ -amino acid or its homologs or isomers
  • R 20 is hydrogen or (C 1 -C 4 ) -alkyl, or
  • R 21 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 22 is hydrogen or (Ci-CVi-alkyl, or
  • R i and R 2 together with the atoms to which they are attached form a 3- to 7-membered carbocycle, R 23 is (C 1 -C 4 ) -alkyl,
  • R 24 is hydrogen or (C 1 -C 4) -alkyl
  • R 27 is hydrogen or (C 1 -C 4) -alkyl, linear (C 2 -C 10) -alkanediyl or a group of the formula where p is a number from 2 to 6,
  • ## 4 denotes the point of attachment to the nitrogen atom, wherein (C 2 -C 10) -alkanediyl may be substituted with 1 to 4 substituents independently selected from the group of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl chain in 1,2-, 1, 3 or 1,4 Relation to each other, with the inclusion of any intervening between carbon atoms carbon atoms to a (Cj-Ce Cyeloa kyl ring or a phenyl ring may be bridged, for a group of the formula
  • # J denotes the point of attachment to the nitrogen atom
  • R 1 is hydrogen or methyl
  • R 2 isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenyl ethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
  • # 5 denotes the point of attachment with the Carbonyi group, the ring A with the -0- moiety contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
  • R 6 is hydrogen, hydroxy or benzyloxy
  • R 3 is hydrogen or methyl
  • R 4 isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzene 1, 1-phenyl ethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
  • R 7 is hydrogen, methyl, ethyl, propyl, f-tert-butyl, benzyl or adamantylmethyl,
  • R s is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R '° is benzoyl
  • R ' 1 for benzyl which may be substituted in the phenyl group with methoxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula
  • # 9 denotes the point of attachment with -CHC (R 26 ) ⁇ T
  • R 12 is phenyl which may be substituted by methoxycarbonyl, carboxyl or a group of the formula ⁇ S (0) 2 0H,
  • R ' 3 is phenyl which may be substituted by methoxycarbonyl or carboxyl
  • R z6 is hydrogen or hydroxy
  • T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl,
  • R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are compounds of the formula (XXXa) as stated above, in which
  • Cys stands for a cy- stone radical which is linked via the sulfur atom of the side chain via a carbon atom of the succinimide
  • ## 1 denotes the point of attachment to the group G
  • L lA is linear (Ci-Cej alkanediyl
  • ## 5 denotes the point of attachment to the group L ' A
  • ## 6 denotes the point of attachment to the group L' B
  • L 5 represents a bond
  • Sets L 6 for a bond
  • R ⁇ 9 is hydrogen
  • R 30 is hydrogen
  • R 3 ' is hydrogen or methyl
  • R 32 is hydrogen or methyl
  • L iB is linear (C 2 -C 6) -alkanediyl
  • L 3 is a bond or ethane, 2-diyl
  • R 14 is hydrogen
  • R l3 is hydrogen
  • R ! 6 is hydrogen or methyl
  • R 17 is hydrogen or methyl
  • R 16 and R i 7 together with the atoms to which they are attached form piperazinyl ring, R 23 is methyl,
  • R 24 is hydrogen or methyl
  • L 2 is linear (C -C -alkanediyl or a group of Fonriei where p is a number of 2 or 3
  • ## 3 denotes the point of attachment to the group B
  • R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-yl methyl, or R 1 and R 2 together with the carbon atom to which they are attached form a (1S, 2R) -2-phenylcyclopropane-1,1-diyl group of the formula
  • R 3 is hydrogen, 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenyietliyl or 1H-indole-methvl sees, oaer
  • R 7 is hydrogen, methyl, ethyl, w-propyl, terr. Butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i0 is benzoyl
  • R ' 1 for benzyl which may be substituted in the Phenylgnippe with Metlioxycarbonvi or Carboxyi, is hydrogen, methyl or a group of the formula stands in which # 9 identifies the point of attachment with -CHCFfaPhenyl,
  • R 12 is phenyl represented by methoxycarbonyl, carboxyi or a group of the formula -S (O) ? .OH can be substituted,
  • R is phenyl which may be substituted by methoxycarbonyl or carboxyi
  • R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are compounds of formula (XXXa) as indicated above, in which Cys is a cysteine radical which is bonded via the sulfur atom of the side chain via a carbon atom of the succinimide
  • L ' is a bond or linear (CVC ft KAJkandiyl
  • L 3 is a bond
  • L 4 is a bond
  • R i 6 is hydrogen or methyl
  • R 17 is hydrogen or methyl
  • L 2 is linear (C 2 -C 6) -alkanediyl or a group of the formula sees, where stands for a number of 2 or 3, the point of attachment with the ⁇ B indicates.
  • R 1 is hydrogen
  • R 2 is benzyl or 1H-indol-3-ylmethyl, or
  • # 5 denotes the point of attachment with the carbonyl group, the ring A with the NO group contained therein for a mono- or bi-cyclic, optionally substituted heterocycle of the formula
  • # 6 denotes the linking moieties with the carbonyl group
  • R 3 is hydrogen
  • R 4 is benzyl or 1 H-indol-3-ylmethyl
  • R 8 is hydrogen
  • R y is hydrogen
  • R 35 is methyl, and their salts, solvates and solvates of the salts.
  • Cys stands for a cysteine residue that is linked via the sulfur atom of the side chain via a carbon atom of the succinimide
  • L stands ! is a bond or linear (C 2 -C 6) -alkanediyl
  • L 3 is a bond
  • R 16 is hydrogen or methyl
  • R '' is hydrogen or methyl, linear (C 2 -C 6) alkanediyl or Gmppe of the formula where p is a number of 2 or 3,
  • ## 3 denotes the point of attachment to the group B
  • # 3 denotes the point of attachment with the nitrogen atom
  • R 1 is hydrogen
  • R 2 is 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
  • # s denotes the point of attachment to the carbonyl group, the ring A with the N-0 -group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
  • R 3 is hydrogen, is 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
  • R 7 is hydrogen
  • R 8 is hydrogen, R is hydrogen,
  • R 35 is methyl
  • Another object of the present invention are compounds of formula (XXXI)
  • L ' is a bond, linear (i-Cio) alkandyl, a group of the formula stands, where
  • n is a number from 2 to 6
  • ## 1 denotes the point of attachment to the group G
  • A is linear (C 2 -C 10) -alkanediyl
  • R 29 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 30 is hydrogen or (C 1 -C 4) -alkyl, or
  • R 29 and R j0 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • R 31 is hydrogen or (C 1 -C 4 -alkyl
  • R J2 is hydrogen or (Ci-CO-alkyl, or
  • R 1 and R 3 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
  • L lB is linear (C 2 -C 10) -alkanediyl, and wherein (C 1 -C 10) -alkanediyl may be substituted with 1 to 4 substituents independently selected from the group of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl chain in 1, 2, 1, 3 or 1, 4 relative to each other, including the optionally present between ilinen carbon atoms to a (Cs-CeVCycloalkyl ring or a phenyl ring may be bridged, for a bond or a group of the formula
  • Q 1 is a 4- to 7-membered heterocycle
  • Q 2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle
  • R ! 8 for hydrogen or R 19 is hydrogen or the side group of a natural ⁇ -amino acid or its
  • R 20 is hydrogen or (C 1 -C 4 ) -alkyl, or
  • R 2! is hydrogen or (C 1 -C 4 ) -alkyl
  • R 22 is hydrogen or (C 1 -C 4 ) -alkyl, or R zl and R z2 together with the atoms to which they are attached form a membered carbocycle,
  • R 27 for hydrogen or stands for linear (C2-Ciü) alkanediyl or for a group of the formula where p is a number from 2 to 6,
  • ## 3 denotes the point of attachment to the group B
  • (C 2 -C 10) -alkanediyl may be substituted with 1 to 4 substituents independently selected from the group consisting of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl chain are substituted in 1, 2, 1, 3 or 1, 4 Relation to each other, including the carbon atoms optionally between them can be bridged to a (Ca-Chj-cycloalkyl ring or a phenyl ring, for a group of formula
  • R ! is hydrogen or methyl
  • R z is isopropyl, isobutyl, .yec-butyl, te; ⁇ -butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyi, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H- Indol-3-ylmethyl, or
  • # 5 denotes the point of attachment with the carbonyl group, the ring A with the N-0 group contained therein for a mono- or bicyclic, optionally substituted Ileterocyclus of Fonnel
  • R 6 is hydrogen, hydroxy or benzyloxy
  • R ! is hydrogen or methyl
  • R 4 is isopropyl, isobutyl, .sea-butyl, te; ⁇ -butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H- Indol-3-ylmethyl, or
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, n-propyl or benzyl, or R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle,
  • R 10 is benzoyl
  • R 1 is benzyl, which may be substituted in the phenyl group with methoxyearbonyl or carboxyi, is hydrogen, methyl or a group of the formula stands in which
  • # 9 identifies the point of attachment with -CHC (R 26 ) -T 2 ,
  • R i2 is phenyl which may be substituted by methoxyearbonyl, carboxyi or a group of the formula -S (0) 2 0H. is phenyl which may be substituted by methoxyearbonyl or carboxyi,
  • R i6 is hydrogen or Hydroxv.
  • T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmetiiyl,
  • R 35 is methyl or Hydroxv, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are compounds of the formula (XXXI) as indicated above, in which
  • L 1 represents a bond, linear (C 2 -C 6) alkanediyl or a group of the formula where m is a number of 2 or 3, ## 1 denotes the point of attachment to the group G,
  • R 18 is hydrogen
  • R 19 is methyl, propan-2-yl, 2-methylpropan-1-yl or 1-methylpropan-1-yl
  • R 20 is hydrogen or (C 1 -C 4 ) -alkyl, or
  • R 21 is hydrogen or methyl
  • R 22 is hydrogen or methyl
  • R 2i and R 22 together with the atoms to which they are attached form a cyclopropyl ring, R 2 'is hydrogen or methyl, linear (C 2 -C 6) alkanediyl or a group of the formula
  • ## 3 denotes the linking item with group B
  • (C-2-Cio) -alkanediyl may be substituted with 1 or 2 substituents methyl, and wherein two carbon atoms of the alkanediyl chain in 1,4-relation to each other, including the carbon atoms optionally between them, be bridged to a phenyl-Rtng can, for a group of formula
  • # J denotes the point of attachment to the nitrogen atom
  • R 1 is hydrogen
  • R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-yl-methyl. or R 1 and R 2 together with the carbon atom to which they are attached form a (1S, 2R) -2-phenylcyclopropane-1,1-diyl group of the formula
  • R 3 is hydrogen, for 1-hydroxy xyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or lH indole methvl sees, oaer
  • R 7 is hydrogen, methyl, ethyl, w-propyl, terr. Butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i0 is benzoyl
  • R ' 1 for benzyl which may be substituted in the phenyl group with Metlioxycarbonvi or carboxy 1, is hydrogen, methyl or a group of the formula stands in which # 9 identifies the point of attachment with -CHCFbPhenyl,
  • R 12 is phenyl which may be substituted with metlioxycarbonyl, carboxy or a group of the formula -S (O) 20H,
  • R is phenyl which may be substituted by methoxycarbonyl or carboxyi
  • R 35 represents methyl or hydroxy, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are compounds of the formula (XXXI) as stated above, in which L 1 represents a bond,
  • R 1 is hydrogen
  • R is benzyl or lif-indol-3-ylmethyl
  • R 3 is hydrogen
  • R 4 is benzyl or 1H-indol-3-ylmethyl, or R 3 and R 4 together with the carbon atom to which they are attached form a (15,2R) -2-phenylcyclopropane-1,1-diyl group of the formula
  • R 7 is hydrogen
  • R 5 is hydrogen
  • R y is hydrogen, R 35 is methyl, and their salts, solvates and solvates of the salts.
  • L 1 is a bond
  • L 2 is linear (C 2 -C 6) -alkanediyl or a group of the formula stands, where p is a number of 2 or 3 which indicates the point of attachment to the group B,
  • R z is 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
  • # 5 denotes the point of attachment with the carbonyl group, the ring A with the -O-moiety contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula stands in which
  • # ö denotes the point of attachment with the carbonyl group
  • R 6 represents hydrogen, hydroxyl or benzyloxy
  • R J represents hydrogen
  • R A is 4-hydroxybenzyl or 1H-indol-3-ynethyl, or
  • R ? stands for hydrogen, stands for hydrogen,
  • R 9 is hydrogen, R 35 is methyl, and their salts, solvates and solvates of the salts.
  • Preferred subject matter of the present invention are compounds of the formulas (XXXa) and (XXXI) selected from the group: N- [6- (3- ⁇ [(2R) -2-amino-2-carboxyethyl] sulfanyl ⁇ -2,5- dioxopyrrolidin-1-yl) hexyl] -N-methyl-L-valyl-iV-i (3R, 4S, 5S) - 1 - ⁇ (2S) -2- [(IR, 2R) -3 - ⁇ [( ⁇ S) - ⁇ -carboxy-2- (1H-indol-3-yl) ethyl] amino ⁇ -1-methoxy-2-methyl-3-oxopropyl] pyrrolidin-1-yl ⁇ -3-methoxy-5-methyl oxoheptan-4-yl] -N-metyl-L-valinamide,
  • a further subject of the present invention are binder active compound conjugates of the general formula (I)
  • n is a number from 1 to 50
  • AK stands for a binder
  • group ⁇ -GL 1 -BL 2 - ⁇ stands for a linker
  • ⁇ denotes the linking position with the group AK
  • ⁇ denotes the linking position with the nitrogen atom
  • D represents a group of the formula
  • R 1 is hydrogen
  • R 2 is 1-hydroxyethyl, benzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
  • # 5 denotes the point of attachment with the Carbonyi group, the ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
  • R 6 is hydrogen, hydroxy or benzyloxy
  • R 3 is hydrogen
  • R 4 is 1-hydroxyethyl, benzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
  • R 7 is hydrogen, methyl, ethyl, w-propyl, terr. Butyl, benzyl or adamantylmethyl,
  • R 8 is hydrogen or methyl
  • R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
  • R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
  • R i0 is benzoyl
  • R ' 1 for benzyl which may be substituted in the Phenylgnippe with methoxycarbonyl or carboxy, stands for hydrogen, methyl or a group of the formula
  • R ' 2 is phenyl which may be substituted by methoxycarbonyl, carboxyi or a group of the formula -SiOjiOH,
  • R 13 is phenyl which may be substituted by methoxycarbonyl or carboxy, represents hydrogen or hydroxy
  • T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmetyl, and their salts, solvates and solvates of the salts.
  • Preferred subject of the invention are binder active ingredient conjugates of the general formula ( ⁇ ), in which n is a number from 1 to 50, AK for AK: or AK 2 is
  • # denotes the point of attachment to the sulfur atom of the binder
  • the point of attachment to the group G denotes, ##
  • the Verknüpfungssielle with the group B denotes, wherein (Ci-Cio) -alkyl having 1 to 4 Substituenlen methyl may be substituted in, and wherein two carbon atoms of the alkanediyl chain in Figure 1, 2-, 1,3- or 1,4-relative to each other, including the carbon atoms which may be located between them to a (Ca-Cej-cycloalkyl ring or a phenyl ring may be bridged, for a bond or a group of the formula
  • L 3 is a bond or (C 2 -C 4) -alkanediyl
  • L 4 represents a bond or a group of the formula
  • Q 2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocyci
  • R 14 is hydrogen or (C 5 -C) -alkyl
  • R 15 is hydrogen or (Ci-C4) -alkyl, or
  • R ⁇ and R ' 3 together with the atoms to which they are attached form a 5- or 6-membered heterocyci
  • R 16 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 17 is hydrogen or (Ci-C 4 ) -alkyl, or
  • R 16 and R 17 together with the atoms to which they are attached form a 5- or 6-membered heterocyci
  • R 18 is hydrogen or (C 1 -C 4 ) -alkyl
  • R 19 is hydrogen or the side group of a natural ⁇ -amino acid or its homologs or isomers
  • R 20 is hydrogen or (C 1 -C 4 ) -alkyl, or

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouveaux conjugués liant-principe actif (ADC) de N,N-dialkylauristatines, ciblant C4,4a, des métabolites actifs de ces ADC, des procédés de préparation de ces ADC, l'utilisation de ces ADC pour le traitement et/ou la prévention de maladies ainsi que l'utilisation de ces ADC pour la production de médicaments servant au traitement et/ou à la prévention de maladies, notamment de maladies hyperprolifératives et/ou angiogéniques, telles que les maladies cancéreuses. De tels traitements peuvent être effectués en tant que monothérapie ou également en combinaison avec d'autres médicaments ou d'autres mesures thérapeutiques.
EP12718624.5A 2011-04-21 2012-04-20 Nouveaux conjugués liant-principe actif (adc) et leur utilisation Withdrawn EP2699268A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP19150066.9A EP3501546A3 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués cystéine-principe actif et leur utilisation
EP12718624.5A EP2699268A2 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués liant-principe actif (adc) et leur utilisation

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
EP11163472 2011-04-21
EP11163470 2011-04-21
EP11163474 2011-04-21
EP11163467 2011-04-21
EP11168556 2011-06-01
EP11168558 2011-06-01
EP11168557 2011-06-01
EP11168559 2011-06-01
EP11193623 2011-12-14
EP11193618 2011-12-14
EP11193621 2011-12-14
EP11193609 2011-12-14
PCT/EP2012/057247 WO2012143497A2 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués liant-principe actif (adc) et leur utilisation
EP12718624.5A EP2699268A2 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués liant-principe actif (adc) et leur utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19150066.9A Division EP3501546A3 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués cystéine-principe actif et leur utilisation

Publications (1)

Publication Number Publication Date
EP2699268A2 true EP2699268A2 (fr) 2014-02-26

Family

ID=45976407

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12718624.5A Withdrawn EP2699268A2 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués liant-principe actif (adc) et leur utilisation
EP19150066.9A Withdrawn EP3501546A3 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués cystéine-principe actif et leur utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19150066.9A Withdrawn EP3501546A3 (fr) 2011-04-21 2012-04-20 Nouveaux conjugués cystéine-principe actif et leur utilisation

Country Status (16)

Country Link
US (7) US20140127240A1 (fr)
EP (2) EP2699268A2 (fr)
JP (3) JP2014515753A (fr)
KR (2) KR102023496B1 (fr)
CN (3) CN106117312A (fr)
AR (2) AR086364A1 (fr)
AU (3) AU2012244673A1 (fr)
BR (1) BR112013027119A8 (fr)
CA (3) CA3027793A1 (fr)
IL (2) IL228841A (fr)
MX (1) MX2013012253A (fr)
RU (2) RU2610336C2 (fr)
SG (2) SG10201702384PA (fr)
TW (2) TWI636793B (fr)
WO (4) WO2012143499A2 (fr)
ZA (1) ZA201307955B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
ES2528956T3 (es) * 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
CA2813056C (fr) 2010-09-29 2018-09-18 Bayer Intellectual Property Gmbh N-carboxyalkyl-auristatines et leur utilisation
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
RU2610336C2 (ru) * 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
RU2014128467A (ru) * 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
WO2014093379A1 (fr) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Composés auristatine et leurs conjugués
CN105051032B (zh) * 2013-01-03 2017-08-15 赛特瑞恩股份有限公司 抗体‑连接子‑药物偶联物、其制法及包含其的抗癌药物组合物
ES2741207T3 (es) 2013-03-15 2020-02-10 Zymeworks Inc Compuestos citotóxicos y antimitóticos, y métodos de uso de los mismos
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
EP3003387A1 (fr) * 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions et procédés permettant de conjuguer des anticorps activables
US20160250349A1 (en) * 2013-10-25 2016-09-01 Bayer Pharma Aktiengesellschaft A novel stable formulation
WO2015095223A2 (fr) * 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
BR112016012538A2 (pt) 2013-12-17 2017-09-26 Novartis Ag peptídeos citotóxicos e conjugados dos mesmos
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
CN106255513B (zh) 2013-12-27 2022-01-14 酵活有限公司 用于药物偶联物的含磺酰胺连接系统
CA2935064C (fr) 2013-12-27 2023-06-27 Zymeworks Inc. Conjugues var2csa-medicament
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
US9260478B2 (en) 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
SG11201609739UA (en) 2014-05-28 2016-12-29 Agensys Inc Derivatives of dolaproine-dolaisoleuine peptides
EP3154997B9 (fr) 2014-06-13 2021-04-14 Novartis AG Dérivés d'auristatine et conjugués de ceux-ci
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
CN111150851A (zh) * 2015-02-15 2020-05-15 江苏恒瑞医药股份有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
CA2978857C (fr) 2015-03-19 2021-04-20 Hangzhou Dac Biotech Co., Ltd Nouveaux lieurs hydrophiles et conjugues ligand-medicament les comprenant
EP3283522A1 (fr) * 2015-04-17 2018-02-21 Spring Bioscience Corporation Anticorps, compositions et procédés d'immunohistochimie permettant la détection de c4.4a
EP3286172B1 (fr) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Inhibiteurs de lsd1 et leurs utilisations
WO2015151079A2 (fr) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Analogues d'auristatine et leur conjugués avec des molécules de liaison cellulaire
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
JP6928354B2 (ja) * 2015-07-24 2021-09-01 ペティット，ジョージ，ロバート クインスタチン化合物
US10722593B2 (en) 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
BR112018016983A2 (pt) 2016-02-26 2018-12-26 Jiangsu Hengrui Medicine Co., Ltd. nova toxina e método de preparação de intermediário da mesma
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2017216028A1 (fr) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament spécifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
TWI750194B (zh) * 2016-07-05 2021-12-21 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｇｆｒ抗體-藥物偶聯物及其在醫藥上的應用
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
DK3532459T3 (da) 2016-10-26 2023-10-30 Constellation Pharmaceuticals Inc Lsd1-hæmmere og medicinske anvendelser deraf
KR102628678B1 (ko) 2016-12-21 2024-01-25 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
CA3047491A1 (fr) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Promedicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
EP3651798A1 (fr) * 2017-07-12 2020-05-20 Nouscom AG Composition de vaccin à base de néoantigènes pour le traitement du cancer
US10646585B2 (en) 2017-09-15 2020-05-12 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and ligand-drug conjugates thereof
CN107998453B (zh) * 2017-12-12 2020-09-25 中山大学附属第一医院 一种表面改性的脱细胞基质及其改性方法
GB201721265D0 (en) * 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CN112040951A (zh) 2018-01-31 2020-12-04 拜耳股份公司 具有nampt抑制剂的抗体药物缀合物(adc)
TW202003047A (zh) 2018-03-23 2020-01-16 美商西雅圖遺傳學公司 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
WO2021013693A1 (fr) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament (adc) avec des inhibiteurs de nampt
US20230059690A1 (en) * 2020-01-06 2023-02-23 Cytomx Therapeutics, Inc. Anti-psma antibodies, antibody drug conjugates, and methods of use thereof
US20240024499A1 (en) * 2020-11-19 2024-01-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
AU2021381419A1 (en) * 2020-11-20 2023-06-29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Modified egfr antibody with reduced affinity, drug conjugate, and use thereof
EP4319746A1 (fr) * 2021-04-06 2024-02-14 Hemoshear Therapeutics, Inc. Méthodes de traitement de l'acidémie méthylmalonique et de l'acidémie propionique
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP4420682A1 (fr) * 2021-10-12 2024-08-28 Chengdu Scimount Pharmatech Co., Ltd. Conjugué lieur-médicament ciblé hautement stable
EP4433096A1 (fr) 2021-11-19 2024-09-25 Ardeagen Corporation Agents de liaison de gpc3, leurs conjugués et leurs procédés d'utilisation
CN114149343B (zh) * 2021-12-06 2023-10-20 中节能万润股份有限公司 一种高纯度1,4-二氰基-2-丁烯的制备方法
WO2023240135A2 (fr) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Chélateurs et conjugués bifonctionnels
WO2023237050A1 (fr) * 2022-06-09 2023-12-14 Beigene, Ltd. Conjugués anticorps-médicament
WO2024023735A1 (fr) * 2022-07-27 2024-02-01 Mediboston Limited Dérivés d'auristatine et conjugués de ceux-ci
CN116239513B (zh) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500992A (fr) 1980-06-13 1982-06-03
FR2499737B1 (fr) 1981-02-12 1985-07-05 Laudren Cie Sa Ets M Circuit d'alarme pour systemes de surveillance de postes telephoniques publics a prepaiement
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
DE3265843D1 (en) 1981-07-30 1985-10-03 Shell Int Research Process for the preparation of carbonate esters
DE3223868A1 (de) 1982-06-25 1983-12-29 Friedrich 8541 Röttenbach Schweinfurter Turbinenpumpe
HUT36107A (en) 1982-12-04 1985-08-28 Lilly Industries Ltd Process for production of new aurone-derivatives and medical preparatives consisting of such compounds
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2163883B (en) 1984-08-29 1989-02-01 British Aerospace Data processing arrangement
FR2576708B1 (fr) 1985-01-25 1987-04-30 Novatome Generateur de vapeur dont le fluide caloporteur est du metal liquide et dont la detection des fuites est effectuee par prelevement de ce metal liquide
US4606662A (en) 1985-01-31 1986-08-19 International Business Machines Corporation Single stepping motor ribbon and correction feed and lift system
US4640839A (en) 1985-07-01 1987-02-03 Nestec S.A. Agglomeration process
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
DK0595798T3 (da) 1989-10-20 1999-09-27 Medarex Inc Bispecifikke heteroantistoffer med dobbelte effektorfunktioner
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
WO1992008802A1 (fr) 1990-10-29 1992-05-29 Cetus Oncology Corporation Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
DK0511011T3 (da) 1991-04-26 1997-03-10 Surface Active Ltd Nye antistoffer og fremgangsmåde til anvendelse heraf
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
EP0859841B1 (fr) 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
WO1997035616A1 (fr) 1996-03-25 1997-10-02 Pacific Northwest Cancer Foundation Anticorps monoclonaux de l'antigene membranaire specifique de la prostate
CA2338000C (fr) * 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives 4-thiomaleimidiques solubles dans l'eau et methodes pour les produire
SK16522001A3 (sk) 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
WO2000069472A2 (fr) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Composes de promedicaments anti-tumoraux actives par des enzymes
IL147638A0 (en) 1999-07-29 2002-08-14 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP1220919A2 (fr) 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts C4.4a, antigene associee a la metastase
CA2400868C (fr) 2000-02-25 2012-12-04 Ira Pastan Scfv anti-egfrviii possedant une cytotoxicite et un rendement ameliores, immunotoxines a base de ces scfv et procede d'utilisation associe
AU2001258567A1 (en) 2000-05-19 2001-11-26 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
DE60230868D1 (de) 2001-04-26 2009-03-05 Biogen Inc Criptoblockierende antikörper und deren verwendung
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ATE446317T1 (de) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
CZ200438A3 (cs) 2001-06-13 2004-06-16 Genmab A/S Název neuveden
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2003026577A2 (fr) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-aminobenzyl ether dans des agents d'administration de medicaments
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
AU2003261071C1 (en) 2002-03-13 2008-12-11 Biogen Idec Ma Inc. Anti-AlphavBeta6 antibodies
JP2005520566A (ja) 2002-03-22 2005-07-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ特異的抗体
WO2005056606A2 (fr) 2003-12-03 2005-06-23 Xencor, Inc Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
KR101143035B1 (ko) 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
AU2004229543A1 (en) 2003-04-11 2004-10-28 Medimmune, Llc EphA2 and non-neoplastic hyperproliferative cell disorders
KR20140142311A (ko) 2003-06-27 2014-12-11 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
DK1660513T5 (da) 2003-07-21 2011-07-18 Immunogen Inc CA6 antigen-specifikt, cytotoksisk konjugat og fremgangsmåder til anvendelse heraf
KR101192496B1 (ko) 2003-11-06 2012-10-18 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP2332990A1 (fr) 2004-03-19 2011-06-15 Imclone LLC Anticorps de récepteur de facteur de croissance anti-épidermique humain
ES2549077T3 (es) * 2004-04-07 2015-10-22 Genentech, Inc. Espectrometría de masas de conjugados de anticuerpos
MX2007003907A (es) * 2004-10-05 2007-05-21 Genentech Inc Agentes terapeuticos con toxicidad reducida.
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
DE602005022928D1 (de) * 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
AU2005314392B2 (en) 2004-12-09 2011-04-14 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
ATE462726T1 (de) 2005-01-07 2010-04-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
EP1917020B1 (fr) 2005-07-07 2016-05-25 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
WO2007008848A2 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications carboxy phenylalanine a la terminaison c
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
CA2621502A1 (fr) * 2005-09-07 2007-03-15 Medimmune, Inc. Anticorps anti-recepteur eph conjugues a des toxines
EP1934261B1 (fr) 2005-09-26 2014-10-29 Medarex, L.L.C. Anticorps monoclonaux humains diriges contre cd70
EP2548583A3 (fr) * 2005-11-10 2013-02-27 Curagen Corporation Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
ES2567402T3 (es) * 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
WO2008004834A1 (fr) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf
DK2066349T3 (da) 2006-09-08 2012-07-09 Medimmune Llc Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme
WO2008028686A2 (fr) 2006-09-10 2008-03-13 Glycotope Gmbh Système de production à haut rendement, entièrement humain, pour anticorps et protéines améliorés
JP5562031B2 (ja) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Ｈｍ１．２４を標的とする最適化抗体
WO2008133641A2 (fr) * 2006-10-11 2008-11-06 Curagen Corporation Anticorps dirigés contre la gpnmb et leurs utilisations
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2099823B2 (fr) 2006-12-01 2022-02-09 Seagen Inc. Agents se liantà des cibles variables et utilisations de ceux-ci
WO2008140603A2 (fr) 2006-12-08 2008-11-20 Macrogenics, Inc. MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
WO2009026274A1 (fr) 2007-08-22 2009-02-26 Medarex, Inc. Attachement spécifique d'un site de médicaments ou autres agents à des anticorps synthétisés par génie génétique avec des extensions c-terminales
US8039597B2 (en) 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
CA2698287A1 (fr) 2007-09-07 2009-03-12 Agensys, Inc. Anticorps et molecules apparentees qui se lient aux proteines 24p4c12
AU2008308956B2 (en) * 2007-10-01 2013-03-14 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
ES2569513T3 (es) 2007-11-26 2016-05-11 Bayer Intellectual Property Gmbh Anticuerpos antimesotelina y usos de los mismos
HUE024291T2 (en) 2007-12-26 2016-01-28 Biotest Ag Immunoconjugates and Applications for CD138
WO2009080829A1 (fr) 2007-12-26 2009-07-02 Biotest Ag Agents ciblant cd138 et leurs applications
IL287292B (en) * 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
US20110126727A1 (en) 2008-02-25 2011-06-02 Prittie Allan R Raised Image Plate Construction with Regions of Varying Support Thickness Beneath the Image Areas
AU2009223124B2 (en) * 2008-03-14 2015-03-26 Genentech, Inc. Genetic variations associated with drug resistance
DK2842575T3 (da) 2008-03-18 2017-11-27 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
SI2247304T1 (sl) 2008-04-02 2016-11-30 Macrogenics, Inc. Protitelesa, specifična za HER2/neu, in postopki za njihovo uporabo
ES2544971T3 (es) * 2008-05-13 2015-09-07 Genentech, Inc. Análisis de conjugados de fármacos y anticuerpos mediante espectrometría de masas con captura por afinidad basada en esferas
JP5719298B2 (ja) 2008-08-29 2015-05-13 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組換え抗上皮増殖因子受容体抗体組成物
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
KR20110128320A (ko) 2009-03-31 2011-11-29 로슈 글리카트 아게 인간화 항-ｅｇｆｒ ｉｇｇ1 항체 및 이리노테칸으로의 암 치료
US20120094863A1 (en) 2009-06-19 2012-04-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
DK2486141T3 (en) 2009-10-07 2018-04-23 Macrogenics Inc FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
ES2528956T3 (es) * 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
CA2813056C (fr) 2010-09-29 2018-09-18 Bayer Intellectual Property Gmbh N-carboxyalkyl-auristatines et leur utilisation
MA34881B1 (fr) * 2010-12-20 2014-02-01 Genentech Inc Anticorps et immunoconjugués anti-mésothéline
US9302799B2 (en) * 2011-02-17 2016-04-05 Sabic Global Technologies B.V. Method for bulk transporting 2,6-xylenol susceptible to oxidative discoloration
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
RU2014128467A (ru) 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US20130095123A1 (en) 2013-04-18
CA2833690A1 (fr) 2012-10-26
TW201722483A (zh) 2017-07-01
WO2012143499A2 (fr) 2012-10-26
AU2012244675A1 (en) 2013-11-28
CN103764170A (zh) 2014-04-30
CA3027793A1 (fr) 2012-10-26
JP2014512375A (ja) 2014-05-22
TWI582112B (zh) 2017-05-11
CN106117312A (zh) 2016-11-16
BR112013027119A2 (pt) 2017-09-26
AU2017203928A1 (en) 2017-07-06
IL228841A (en) 2017-07-31
WO2012143495A2 (fr) 2012-10-26
WO2012143499A3 (fr) 2012-12-13
US20150030618A1 (en) 2015-01-29
AU2017203928B2 (en) 2019-02-21
WO2012143496A3 (fr) 2013-03-21
EP3501546A3 (fr) 2019-09-18
NZ615839A (en) 2015-11-27
CN103826661A (zh) 2014-05-28
RU2013151599A (ru) 2015-05-27
CA2833477A1 (fr) 2012-10-26
IL248036B (en) 2018-04-30
CN103826661B (zh) 2019-03-05
KR102023496B1 (ko) 2019-09-20
EP3501546A2 (fr) 2019-06-26
US20130122024A1 (en) 2013-05-16
KR20140122167A (ko) 2014-10-17
US20150246136A1 (en) 2015-09-03
JP6250735B2 (ja) 2017-12-20
US20130066055A1 (en) 2013-03-14
KR20140122649A (ko) 2014-10-20
TW201305218A (zh) 2013-02-01
WO2012143497A3 (fr) 2013-03-21
AR086364A1 (es) 2013-12-11
JP2014515753A (ja) 2014-07-03
AR086363A1 (es) 2013-12-11
WO2012143496A2 (fr) 2012-10-26
SG194567A1 (en) 2013-12-30
TWI636793B (zh) 2018-10-01
AU2012244675B2 (en) 2017-06-29
WO2012143497A2 (fr) 2012-10-26
US20160193359A1 (en) 2016-07-07
BR112013027119A8 (pt) 2018-03-06
SG10201702384PA (en) 2017-05-30
US8992932B2 (en) 2015-03-31
RU2610336C2 (ru) 2017-02-09
AU2012244673A1 (en) 2013-11-28
JP2016175941A (ja) 2016-10-06
WO2012143495A3 (fr) 2012-12-13
JP6088488B2 (ja) 2017-03-01
IL228841A0 (en) 2013-12-31
MX2013012253A (es) 2014-02-17
RU2013151600A (ru) 2015-05-27
ZA201307955B (en) 2015-01-28
US20140127240A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
AU2017203928B2 (en) Novel binder-drug conjugates (ADCs) and their use
EP2790731A2 (fr) Conjuguées de lieur fgfr et de principe actif
EP3086814B1 (fr) Conjugués de liants (conjugué anticorps-médicament) comprenant des inhibiteurs de la protéine kinésine du fuseau
NZ615839B2 (en) Novel binder-drug conjugates (adcs) and their use
NZ625745B2 (en) FGFR antibody drug conjugates (ADCs) and the use thereof
TW201302799A (zh) 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（一）
TW201339175A (zh) 新黏合劑－藥物接合體（ａｄｃ）及其用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131022

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192463

Country of ref document: HK

17Q First examination report despatched

Effective date: 20180620

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200620

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192463

Country of ref document: HK